DOI QR코드

DOI QR Code

혈액투석

Hemodialysis

  • 이영기 (한림대학교 의과대학 내과학교실, 한림대학교 신장연구소) ;
  • 오지은 (한림대학교 의과대학 내과학교실, 한림대학교 신장연구소)
  • Lee, Young-Ki (Department of Internal Medicine, Hallym University College of Medicine, Hallym Kidney Research Institute) ;
  • Oh, Jieun (Department of Internal Medicine, Hallym University College of Medicine, Hallym Kidney Research Institute)
  • 발행 : 2014.02.01

초록

With the widespread availability of dialysis, the lives of end-stage renal disease patients have been prolonged over the past fifty years. Hemodialysis relies on the diffusion of molecules across a semipermeable membrane along the concentration gradient. In addition to diffusion, movement of waste products from the circulation into the dialysate can occur as a result of convective clearance. Use of high-flux dialyzer has increased the removal of the middle molecules such as ${\beta}_2$-microglobulin. Recently on-line hemodiafiltration which combined the hemodialysis and hemofiltration to increase the convective clearance of the large molecules has been available. About the hemodialysis adequacy, the result of hemodialysis (HEMO) study suggests that increasing the dose to greater than a single-pool $Kt/V_{urea}$ 1.4 does not improve the survival of the patients. While the technical and scientific improvement in hemodialysis has led to a noticeable improvement in the survival of the dialysis patients, cardiovascular mortality and event rates are extraordinarily high in dialysis population. In addition to hemodialysis treatment, nephrologists taking care of dialysis patients must recognize and treat the diverse complications that can result from the loss of kidney function.

키워드

참고문헌

  1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
  2. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis 2003;41:310-318. https://doi.org/10.1053/ajkd.2003.50038
  3. ESRD Registry Committee, Korean Society of Nephrology. Current renal replacement therapy in Korea; Insan memorial dialysis registry, 2012. Korean J Nephrol 2013;32(Suppl 2):S7-35.
  4. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease: chapter 5: referral to specialists and models of care. Kidney Int Suppl 2013;3:112-119. https://doi.org/10.1038/kisup.2012.68
  5. Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010;363:609-619. https://doi.org/10.1056/NEJMoa1000552
  6. Streja E, Nicholas SB, Norris KC. Controversies in timing of dialysis initiation and the role of race and demographics. Semin Dial 2013;26:658-666. https://doi.org/10.1111/sdi.12130
  7. Kolff WJ, Berk HT, ter Welle M, van der LEY AJ, van Dijk EC, van Noordwijk J. The artificial kidney: a dialyser with a great area: 1944. J Am Soc Nephrol 1997;8:1959-1965.
  8. Scribner BH, Caner JE, Buri R, Quinton W. The technique of continous hemodialysis. Trans Am Soc Artif Intern Organs 1960;6:88-103.
  9. Quinton W, Dillard D, Scribner BH. Cannulation of blood vessels for prolonged hemodialysis. Trans Am Soc Artif Intern Organs 1960;6:104-113.
  10. Kim HC. Nephrology for block lecture. 2nd ed. Seoul: E-public, 2009.
  11. Vascular Access Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006;48(Suppl 1):S248-273. https://doi.org/10.1053/j.ajkd.2006.04.040
  12. Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007;357:1316-1325. https://doi.org/10.1056/NEJMra071313
  13. Sirich TL, Funk BA, Plummer NS, Hostetter TH, Meyer TW. Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol 2013 Nov 14 [Epub]. http://dxr.doi.org/10.1681/ASN.2013060597.
  14. Schiffl H. High-flux dialyzers, backfiltration, and dialysis fluid quality. Semin Dial 2011;24:1-4. https://doi.org/10.1111/j.1525-139X.2010.00786.x
  15. Asci G, Tz H, Ozkahya M, et al. The impact of membrane permeability and dialysate purity on cardiovascular outcomes. J Am Soc Nephrol 2013;24:1014-1023. https://doi.org/10.1681/ASN.2012090908
  16. Kim EY, Lee YK, Lee SM, et al. Low-dose nafamostat mesilate in hemodialysis patients at high bleeding risk. Korean J Nephrol 2011;30:61-66.
  17. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-534. https://doi.org/10.1038/ki.1985.160
  18. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48(Suppl 1):S2-90. https://doi.org/10.1053/j.ajkd.2006.03.051
  19. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019. https://doi.org/10.1056/NEJMoa021583
  20. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4:1205-1213.
  21. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med 2010;363:1833-1845. https://doi.org/10.1056/NEJMra0902710
  22. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-1137. https://doi.org/10.1038/sj.ki.5002466
  23. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084. https://doi.org/10.1056/NEJMoa062276
  24. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-1407. https://doi.org/10.1056/NEJMoa0810177
  25. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032. https://doi.org/10.1056/NEJMoa0907845
  26. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098. https://doi.org/10.1056/NEJMoa065485
  27. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248. https://doi.org/10.1056/NEJMoa043545
  28. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007;298:1163-1170. https://doi.org/10.1001/jama.298.10.1163
  29. Locatelli F, Altieri P, Andrulli S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 2010;21:1798-1807. https://doi.org/10.1681/ASN.2010030280
  30. Lin CL, Yang CW, Chiang CC, Chang CT, Huang CC. Longterm on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif 2001;19:301-307. https://doi.org/10.1159/000046958
  31. Ok E, Asci G, Toz H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013;28:192-202. https://doi.org/10.1093/ndt/gfs407
  32. Maduell F, Moreso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013;24:487-497. https://doi.org/10.1681/ASN.2012080875

피인용 문헌

  1. 혈액투석액 온도가 투석 환자의 혈압, 심부체온 및 신체적 증상에 미치는 효과 vol.29, pp.6, 2014, https://doi.org/10.7475/kjan.2017.29.6.604
  2. 동정맥루를 가진 혈액투석 환자의 자가관리 측정도구 개발 및 평가 vol.29, pp.6, 2014, https://doi.org/10.7475/kjan.2017.29.6.637
  3. 감염 예방을 위한 인공신장실 의료 환경에 대한 고찰 - 근거 기반의 디자인 중심으로 vol.24, pp.3, 2014, https://doi.org/10.15682/jkiha.2018.24.3.49
  4. 치료 가능한 사망으로 측정한 우리나라 지역 간 건강수준의 격차 vol.31, pp.1, 2014, https://doi.org/10.4332/kjhpa.2021.31.1.100